Drug intelligence / Profile preview

NLP91

Development stage: Preclinical
Lead developer: NovaLead Pharma
Modality: Small Molecules
Administration: Topical

Overview

NLP91 is a small molecule drug candidate developed by NovaLead Pharma for the treatment of psoriasis and other inflammatory skin diseases. It is based on an FDA-approved generic drug molecule that has demonstrated novel anti-inflammatory activity, discovered through in-silico screening and validated in vitro. The drug is being developed as a topical therapy targeting mild-to-moderate psoriasis, which represents the majority of psoriasis cases. As of March 2025, NLP91 remains in preclinical development with ongoing animal model studies to further validate its efficacy and safety.

Beyond the preview

Go deeper on NLP91.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NLP91.

Explore the full profile